Recurrent Head & Neck Cancer Squamous Cell Carcinoma – 2019 Pipeline Insight Study – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Recurrent
Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Insight, 2019”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

The report offers comprehensive insights of the pipeline (under
development) therapeutics scenario and growth prospects across Recurrent
Head And Neck Cancer Squamous Cell Carcinoma development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental
Stages:

• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

Scope of the Report

• The report provides a snapshot of the pipeline development for
  Recurrent Head And Neck Cancer Squamous Cell Carcinoma
• The report covers pipeline activity across the complete product
  development cycle i.e. clinical, pre-clinical and discovery stages for
  Recurrent Head And Neck Cancer Squamous Cell Carcinoma
• The report provides pipeline product profiles which includes product
  description, developmental activities, licensors & collaborators and
  chemical information
• Provides pipeline assessment by monotherapy and combination therapy
  products, stage of development, route of administration, and molecule
  type for Recurrent Head And Neck Cancer Squamous Cell Carcinoma
• The report also covers the dormant and discontinued pipeline projects
  related to Recurrent Head And Neck Cancer Squamous Cell Carcinoma

Reasons to Buy

• Establish comprehensive understanding of the pipeline activity across
  this Recurrent Head And Neck Cancer Squamous Cell Carcinoma to
  formulate effective R&D strategies
• Gather information of the emerging competitors having potentially
  lucrative portfolio in this space and create effective counter
  strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target
  finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the
  pipeline depth and focus of Recurrent Head And Neck Cancer Squamous
  Cell Carcinoma therapeutics
• Devise in licensing and out licensing strategies by identifying
  prospective partners with the most attractive projects to enhance and
  expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and
  understanding the factors that might have halted their progress

Key Topics Covered

1. Report Introduction

2. Recurrent Head And Neck Cancer Squamous Cell Carcinoma
Overview

3. Pipeline Therapeutics

• An Overview of Pipeline Products for Recurrent Head And Neck Cancer
  Squamous Cell Carcinoma

4. Comparative Analysis

5. Products in Clinical Stage

• Product Description
• Research and Development
• Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

• Product Description
• Research and Development
• Product Development Activities

7. Therapeutic Assessment

• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

8. Inactive Products

• Product Description
• Research and Development
• Product Development Activities

Companies Mentioned

• Advaxis
• Amgen Inc.
• AstraZeneca PLC
• AVEO Pharmaceuticals
• Critical Outcome Technologies Inc.
• Daiichi Sankyo Company
• Genentech
• Glycotope GmbH
• Immunovative Therapies
• Laboratoires Pierre Fabre S.A.
• Mabion S.A.
• MedImmune
• Merck & Co.
• Novartis AG
• Oncolytics Biotech Inc.
• Ono Pharmaceutical Co.
• Panacea Biotec Limited

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/r79vvk

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs , Skin
Cancer Drugs